TMCnet News

Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Endo International plc (ENDP) Investors
[June 23, 2020]

Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Endo International plc (ENDP) Investors


Glancy Prongay & Murray LLP ("GPM"), a national investors rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased Endo International plc ("Endo" or "the Company") (NASDAQ: ENDP) securities between August 8, 2017 and June 10, 2020, inclusive (the "Class Period"). Endo investors have until August 18, 2020 to file a lead plaintiff motion.

If you suffered a loss on your Endo investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/endo-international-plc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.

On June 10, 2020, the New York Department of Financial Services ("DFS") announced that it "has filed charges and initiated administrative proceedings against Endo International plc" and certain of its subsidiaries in connectionwith "DFS' ongoing investigation into the entities that created and perpetuated the opioid crisis." According to the DFS press release, "Endo . . . [k]nowingly furthered a false narrative to legitimize opioids as appropriate for broad treatment of pain by downplaying their long-known addictive nature and risks"; "[m]isrepresented the safety and efficacy of opioids, without legitimate scientific substantiation"; and "[d]eployed a large sales force to target healthcare providers directly with these misrepresentations."



On this news, the Company's share price fell $0.66, or nearly 15%, to close at $3.85 per share on June 10, 2020, thereby injuring investors.

The complaint alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose: (1) that the full scope of Endo's and/or its subsidiaries' contributions to the opioid crisis, including, but not limited to, their opioid products' disproportionately negative impact on New York, one of the most populous states in the U.S., as well as the fraud that Defendants perpetrated on the New York insurance market; (2) that part of that contribution to the crisis included Endo publishing and disseminating false information to health care providers regarding the risks and benefits of opioids; (3) that the foregoing, once revealed, was foreseeably likely to subject Endo and/or its subsidiaries to increased regulatory scrutiny and enforcement, as well as significant financial and/or reputational harm, particularly with respect to New York; and (4) that, as a result, the Company's public statements were materially false and misleading at all relevant times.


Follow us for updates on LinkedIn, Twitter, or Facebook.

If you purchased Endo securities during the Class Period, you may move the Court no later than August 18, 2020 to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


[ Back To TMCnet.com's Homepage ]